Navigation Links
New prediction model to improve patient survival after paracetamol-related liver failure
Date:4/9/2014

London, UK, Thursday 10 April 2014: In the UK paracetamol toxicity is the most common cause of ALF and has a high mortality rate. It is estimated that 150 to 200 deaths and 15 to 20 LTs occur as a result of poisoning each year in England and Wales. LT is the definitive treatment for ALF patients who meet the criteria for transplantation but the current means of selection for LT (the King's College Criteria) are not ideal and do not assess changes in prognostic measures over time or quantify the mortality risk for individual patients.

Experts in London from King's College Hospital and the Foundation for Liver Research studied a large group of patients (500) with paracetamol-related ALF and developed and validated a novel outcome prediction model using sequentially-assessed measures to generate an individualised mortality risk prediction without LT.

320 patients (admitted 2000-2007) formed a training dataset and 180 (2008-2012) were studied for testing over a three-day period after admission to a specialist intensive care unit.

Age, encephalopathy and cardiovascular failure severity on admission, as well as the dynamic variables of arterial pH, lactate and creatinine over the first three days were found to be the best predictors. Prediction of non-transplanted 15-day survival in the training and test groups was 0.95 (95% CI 0.93-0.98) and 0.91 (0.82-1) respectively: significantly higher than the standard Kings College Criteria (0.78 (0.72-0.83), with quantified survival predictions being provided for individual patients.1

Prof. Markus Peck-Radosavljevic, Secretary-General of the European Association for the Study of the Liver and Associate Professor of Medicine, University of Vienna, Austria commented: "Acute liver failure is a devastating condition that triggers a cascade of events that can lead to multiple organ failure and often death."

"This high-performance survival model for paracetamol-induced acute liver failure will enable each individual patient to be assessed quickly and a personalised mortality risk provided. Consequently, this will allow the healthcare professional to make a very informed decision regarding a liver transplant, potentially resulting in improved patient outcomes," he added.

Paracetamol is classified as a mild analgesic and is commonly used for the relief of headaches and other minor aches and pains as well as being a major ingredient in numerous cold and flu remedies. It is widely prescribed and inexpensive to purchase over-the-counter (OTC), making it a common drug taken in overdose. It is particularly toxic when taken in combination with alcohol.

In 1998, the UK government restricted sales of OTC paracetamol to packs of 32 500mg tablets in pharmacies and 16 500mg tablets in non-pharmacy outlets. Pharmacists may provide up to 100 tablets for those with chronic conditions at the pharmacist's discretion


'/>"/>

Contact: Courtney Lock
Courtney.Lock@cohnwolfe.com
44-789-438-6422
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. PTPower.com, the #1 Fitness Marketing Blog, Reveals the Top Fitness Industry Trends and Predictions for 2014
2. Study looks at better prediction for epileptic seizures through adaptive learning approach
3. Getting to grips with seizure prediction
4. Housing Trends the Last Half Of 2013: Housing Analysts Predictions
5. Innovations Announces Univfy IVF Prediction Tests to be Featured in Upcoming Episode
6. Univfy IVF Prediction Tests to Be Featured in Upcoming Episode of Health Heroes, Produced by DMG Productions
7. UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine
8. Prediction of seasonal flu strains improves chances of universal vaccine
9. Breast cancer risk prediction model for African American women underestimates risk
10. Astro Clairvoyant Norah Guide for Premium Astrology Publishes New Blog Series on 2013 Predictions
11. Travel Services MyTSOnline Celebrates the Holidays by Extending Lifetime Memberships and Poking Fun at the Mayan End of World Prediction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... appointment of Mike Finnegan to the position of Executive Vice President, Sales and ... in healthcare technology, telehealth and medical device sales leadership. He has received industry ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... many of the health care industry’s hospitals and provider groups, has announced that ... for select customers. Parasail Health is a San Francisco health-finance startup that has ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article ... reach a staggering $6.81 billion by the year 2024 according to a new report. ... rate than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics & ...
(Date:6/27/2017)... ... June 27, 2017 , ... Atmosera , ... Atmosera Managed Azure Services . The trusted, transparent, and secure solution for the ... growing customer base. Atmosera’s next generation services include integrated capabilities for public, private, ...
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is ... PTSD. Yet less than 20% will receive adequate care due to lack of effective ... receive any care at all. And left untreated, veterans are at an increased risk ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... -- Exactly 50 years ago today, the Monterey Pop Festival opened ... the San Francisco "Summer of Love."  To celebrate the anniversary, ... in strategic market research portals that it will begin delivering ... Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, Embodied ... Startups pitch competition and came away with $25,000 ... is described by Forbes as "entering the life of ... Association as teaching "empathy to medical professionals in an ... was recently named a finalist for the Department of ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
Breaking Medicine Technology: